Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseaseSeptember 1, 2025
Sustainability sessions at IGCF 2025 to discuss the future of cities, oceans, and climateSeptember 1, 2025
Share Facebook Twitter LinkedIn Pinterest Email Subscribe to continue reading Subscribe to get access to the rest of this post and other subscriber-only content. Type your email… Subscribe Already a subscriber?
Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease
